Head and Neck Cancer
- Larynx, Lip, Oral Cavity and PharynxA Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk FeaturesPrincipal Investigator: Aarti Bhatia
- Esophagus, Larynx, Lip, Oral Cavity and PharynxA Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPCAPrincipal Investigator: Aarti Bhatia
- Larynx, Lip, Oral Cavity and PharynxSingle-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Second-Line Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and NeckPrincipal Investigator: Aarti Bhatia
- Larynx, Lip, Oral Cavity and PharynxPhase II Randomized Trial of Adjuvant Radiotherapy With or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)Principal Investigator: Barbara Burtness
- Larynx, Lip, Oral Cavity and PharynxRadiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck CancerPrincipal Investigator: Melissa Rasar Young